000275941 001__ 275941
000275941 005__ 20240229154949.0
000275941 0247_ $$2doi$$a10.3389/fonc.2023.1078725
000275941 0247_ $$2pmid$$apmid:37152008
000275941 0247_ $$2pmc$$apmc:PMC10160457
000275941 0247_ $$2altmetric$$aaltmetric:147158191
000275941 037__ $$aDKFZ-2023-00929
000275941 041__ $$aEnglish
000275941 082__ $$a610
000275941 1001_ $$0P:(DE-He78)2ffc015bc2bdd9ed7a54d29dc063ab75$$aJohn, Lukas$$b0$$eFirst author$$udkfz
000275941 245__ $$aImpact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.
000275941 260__ $$aLausanne$$bFrontiers Media$$c2023
000275941 3367_ $$2DRIVER$$aarticle
000275941 3367_ $$2DataCite$$aOutput Types/Journal article
000275941 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683712653_9235
000275941 3367_ $$2BibTeX$$aARTICLE
000275941 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275941 3367_ $$00$$2EndNote$$aJournal Article
000275941 500__ $$a#EA:A360#
000275941 520__ $$aInfections are a leading cause of morbidity and mortality in patients with multiple myeloma (MM).To examine the effects of modern second-generation novel agent therapy on immune cell subsets, in particular CD4+-T-cells, and infectious complications in patients with relapsed/refractory MM (RRMM), we conducted a prospective cohort study in 112 RRMM patients.Substantially decreased CD4+-T-cells <200/µl before initiation of relapse therapy were detected in 27.7% of patients and were associated with a higher number of previous lines of therapy. Relapse therapy with carfilzomib or pomalidomide showed a significant further decrease of CD4+-T-cells. All novel agents led to a significant decrease of B-cell counts. Overall, infections were frequent with 21.3% of patients requiring antibacterial therapy within the first 3 months of relapse therapy, 5.6% requiring hospitalization. However, in the setting of standard antimicrobial prophylaxis in RRMM patients with very low CD4+-T-cells, no significant association of CD4+T-cell count and an increased risk of infection could be detected.Our findings imply that reduced CD4+-T-cell numbers and infections are common in patients with RRMM. We also demonstrate an association with the number of previous therapies and certain substances suggesting an increased need for personalized prophylaxis strategies for opportunistic infections in this patient cohort.
000275941 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000275941 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275941 650_7 $$2Other$$aCD4+-T-cells
000275941 650_7 $$2Other$$aimmune cell subsets
000275941 650_7 $$2Other$$ainfections
000275941 650_7 $$2Other$$anovel agents
000275941 650_7 $$2Other$$arelapsed refractory multiple myeloma
000275941 7001_ $$0P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aMiah, Kaya$$b1$$udkfz
000275941 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000275941 7001_ $$aMai, Elias K$$b3
000275941 7001_ $$aKriegsmann, Katharina$$b4
000275941 7001_ $$aHundemer, Michael$$b5
000275941 7001_ $$aKaudewitz, Dorothee$$b6
000275941 7001_ $$aMüller-Tidow, Carsten$$b7
000275941 7001_ $$aJordan, Karin$$b8
000275941 7001_ $$aGoldschmidt, Hartmut$$b9
000275941 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc S$$b10$$udkfz
000275941 7001_ $$aGiesen, Nicola$$b11
000275941 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2023.1078725$$gVol. 13, p. 1078725$$p1078725$$tFrontiers in oncology$$v13$$x2234-943X$$y2023
000275941 909CO $$ooai:inrepo02.dkfz.de:275941$$pVDB
000275941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ffc015bc2bdd9ed7a54d29dc063ab75$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000275941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000275941 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000275941 9141_ $$y2023
000275941 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000275941 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000275941 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T13:25:45Z
000275941 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000275941 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000275941 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-08
000275941 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-08
000275941 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:25:45Z
000275941 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000275941 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000275941 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000275941 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000275941 9200_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000275941 980__ $$ajournal
000275941 980__ $$aVDB
000275941 980__ $$aI:(DE-He78)A360-20160331
000275941 980__ $$aI:(DE-He78)C060-20160331
000275941 980__ $$aUNRESTRICTED